Loading…
Mesoblast Limited is projected to rise to $17.12 by 2027, a +17% move from its current price of $14.66. MESO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $14.36 | $14.67 | $14.98 | +0.05% |
| May 30 | $14.24 | $14.67 | $15.12 | +0.10% |
| May 31 | $14.15 | $14.68 | $15.23 | +0.14% |
| Jun 1 | $14.08 | $14.69 | $15.32 | +0.19% |
| Jun 2 | $14.02 | $14.70 | $15.41 | +0.24% |
| Jun 3 | $13.96 | $14.70 | $15.48 | +0.29% |
| Jun 4 | $13.91 | $14.71 | $15.56 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.91 | $14.71 | $15.56 | +0.34% |
| Week 2 | $13.64 | $14.76 | $15.97 | +0.67% |
| Week 3 | $13.44 | $14.81 | $16.31 | +1.01% |
| Week 4 | $13.29 | $14.86 | $16.62 | +1.35% |
| Week 5 | $13.16 | $14.91 | $16.89 | +1.69% |
| Week 6 | $13.04 | $14.96 | $17.15 | +2.03% |
| Week 7 | $12.94 | $15.01 | $17.40 | +2.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.
The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.
The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Mesoblast Limited (MESO) is currently trading at $15.20 per share with a market capitalization of $1.97B. It ranks 2016.
Current price and market position place it among mid-cap healthcare stocks with a focused pipeline in regenerative medicine and a number of Phase III programs.
The multi-year forecast shows a path of rising averages and upside potential. For 2026 the min, avg, and max prices are $13.69, $15.20, and $20.84 respectively, with an ROI of 0 and a NEUTRAL sentiment. Beyond 2026, the outlook becomes progressively more bullish, with the average price climbing to $22.29 by 2030 and continuing higher toward 2040 and 2050, accompanied by meaningful ROIs (e.g., 46.6 by 2030, 259.1 by 2040, and 627.6 by 2050).
These figures frame a longer-term upside despite near-term uncertainty.
A major floor 10.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.5% away) — a key level to hold.
The nearest ceiling, 13.3% above — a clean break opens room to run.
A major ceiling 30.8% above — clearing it would confirm fresh momentum.
Key MESO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MESO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.85 | Sell | $14.83 | Sell |
| MA 10 | $14.82 | Sell | $14.86 | Sell |
| MA 20 | $15.06 | Sell | $14.98 | Sell |
| MA 50 | $15.06 | Sell | $15.27 | Sell |
| MA 100 | $16.07 | Sell | $15.66 | Sell |
| MA 200 | $16.31 | Sell | $15.52 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.53 | Neutral |
| Stoch RSI (14) | 42.92 | Neutral |
| CCI (20) | -62.50 | Neutral |
| Williams %R (14) | -71.05 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -0.54 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 28.95 | Neutral |
| TRIX (15) | -0.12 | Sell |
| Awesome (5,34) | -0.40 | Sell |
| Ultimate (7,14,28) | 38.57 | Neutral |
| Momentum (10) | 0.22 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 14.99 | Sell |
| ADX (14) | 10.22 | Neutral |
| ATR (14) | 0.27 | Info |
The 30-day technical picture is NEUTRAL. The RSI14 sits at 50, and the near-term trend shows the SMA50 at $15.05 versus the SMA200 at $16.31.
Support sits at $14.44 and resistance at $16.61, with a 30-day price range of $13.17 to $17.55. The asset’s typical volatility over the period adds to the trading nuance in this window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.69 | $14.66 | $19.99 | 0% | Neutral | |
| $13.88 | $17.12 | $22.19 | +17% | Neutral | |
| $14.27 | $17.97 | $23.96 | +23% | Bullish | |
| $14.95 | $19.15 | $26.12 | +31% | Bullish | |
| $15.82 | $20.58 | $28.62 | +40% | Bullish | |
| $19.03 | $25.09 | $35.50 | +71% | Bullish | |
| $20.84 | $27.83 | $39.99 | +90% | Bullish | |
| $21.38 | $28.89 | $42.09 | +97% | Bullish | |
| $23.51 | $32.12 | $47.41 | +119% | Bullish | |
| $23.08 | $31.88 | $47.61 | +117% | Bullish | |
| $33.95 | $49.20 | $77.33 | +236% | Bullish | |
| $62.30 | $97.91 | $165.88 | +568% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $13.69 | $14.66 | $17.16 | +0.00% |
| June 2026 | $12.73 | $14.88 | $17.75 | +1.50% |
| July 2026 | $13.02 | $15.31 | $18.46 | +2.92% |
| August 2026 | $12.95 | $15.31 | $18.60 | -0.06% |
| September 2026 | $12.89 | $15.30 | $18.71 | -0.05% |
| October 2026 | $13.27 | $15.82 | $19.46 | +3.38% |
| November 2026 | $13.54 | $16.19 | $20.03 | +2.36% |
| December 2026 | $13.40 | $16.08 | $19.99 | -0.69% |
Click any year to see its month-by-month MESO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Mesoblast Limited's 2026 outlook centres on $14.66, within a $13.69 to $19.99 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, MESO could reach as high as $22.19, with a base case around $17.12 and support toward $13.88 — roughly +17% from $14.66. Price action looks broadly range-bound.
Expect MESO to range from $14.27 to $23.96 through 2028. The $17.97 average target implies a +23% move from current prices. That is up +5% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The MESO price prediction for 2029 points to an average of $19.15 (low $14.95, high $26.12) — a potential gain of +31% on today's $14.66. Momentum favours further upside here.
In 2030, MESO is projected to trade between $15.82 and $28.62, averaging $20.58 — a potential gain of +40% from today's $14.66. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Mesoblast Limited's 2031 outlook centres on $25.09, within a $19.03 to $35.50 range. That is up +22% on the projected 2030 average. That marks a +71% change versus current levels. Momentum favours further upside here.
By 2032, MESO could reach as high as $39.99, with a base case around $27.83 and support toward $20.84 — roughly +90% from $14.66. Buyers look set to stay in control over this stretch.
Expect MESO to range from $21.38 to $42.09 through 2033. The $28.89 average target implies a +97% move from current prices. That is up +4% on the projected 2032 average. Momentum favours further upside here.
The MESO price prediction for 2034 points to an average of $32.12 (low $23.51, high $47.41) — a potential gain of +119% on today's $14.66. Buyers look set to stay in control over this stretch.
In 2035, MESO is projected to trade between $23.08 and $47.61, averaging $31.88 — a potential gain of +117% from today's $14.66. That is -1% versus the projected 2034 average. Momentum favours further upside here.
Mesoblast Limited's 2040 outlook centres on $49.20, within a $33.95 to $77.33 range. That is up +54% on the projected 2035 average. That marks a +236% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, MESO could reach as high as $165.88, with a base case around $97.91 and support toward $62.30 — roughly +568% from $14.66. Momentum favours further upside here.
Investing $1,000 in MESO today (≈ 68.212824 MESO) could be worth
$6,678.68
+$5,678.68 (+568%) by 2050 · US Dollar
Based on the average projected MESO price of $97.91 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MESOwould be worth at today's price.
$1,000 invested in MESO on May 27, 2025 (≈ 91.157701 MESO) would be worth
$1,336.37
+$336.37 (+33.6%) today · 1.34× · US Dollar
Based on a MESO entry price of $10.97 vs. today's $14.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.52 | $1,009.64 | +1.0% |
| 1 month ago | $15.33 | $956.29 | -4.4% |
| 3 months ago | $16.92 | $866.43 | -13.4% |
| 6 months ago | $17.23 | $850.84 | -14.9% |
| 1 year ago | $10.97 | $1,336.37 | +33.6% |
| All time (5.0y) ago | $14.78 | $991.88 | -0.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MESO forecast.
Our base-case forecast reaches $29.00 around 2034.
Implied market cap at $29.00: $3.75B
The multi-year forecast paints an increasingly bullish trajectory after 2026. In 2027 the average price is $18.04 with a min of $14.58 and a max of $23.46, corresponding to an ROI of 18.7.
The forecast continues to show upside through 2028 (avg $18.94, ROI 24.6), 2029 (avg $20.37, ROI 34), and 2030 (avg $22.29, ROI 46.6). By 2040 the average price is $54.59 with a max of $86.48 and an ROI of 259.1, and by 2050 the average reaches $110.60 with a max of $189.18 and an ROI of 627.6. These figures indicate substantial long-run upside, albeit with uncertainty and the typical caveat that they are estimates, not guarantees.
Tap a question to reveal the answer.
In 2030, the forecast shows an avg of $22.29, with a min of $17.07 and a max of $31.17, and an ROI of 46.6, with bullish sentiment.
The forecast turns bullish from 2027 onward, with rising averages and ROIs (e.g., 18.7 in 2027, 46.6 by 2030, 259.1 by 2040, 627.6 by 2050). These figures suggest upside potential, but are estimates and not guarantees.
Yes. The 2040 forecast shows an avg of $54.59 and a max of $86.48, supporting the possibility of reaching or exceeding $50 in that horizon, though not a guarantee.
The 2026 forecast lists min $13.69, avg $15.20, max $20.84, with ROI 0 and sentiment NEUTRAL.
These are estimates, not guarantees. The forecast shows varying sentiment from neutral to bullish across years, with substantial long-term upside indicated by the avg and max values, but actual results depend on many factors and market conditions.
Mesoblast Limited Community Discussion
0Share your Mesoblast Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.